AbCellera Biologics (ABCL) Retained Earnings (2020 - 2026)
AbCellera Biologics filings provide 7 years of Retained Earnings readings, the most recent being -$2.4 million for Q1 2026.
- Quarterly Retained Earnings fell 103.39% to -$2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Mar 2026, down 103.39% year-over-year, with the annual reading at -$29.5 million for FY2025, 573.41% down from the prior year.
- Retained Earnings hit -$2.4 million in Q1 2026 for AbCellera Biologics, up from -$29.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $456.1 million in Q3 2022 and bottomed at -$29.5 million in Q4 2025.
- Average Retained Earnings over 5 years is $194.9 million, with a median of $202.2 million recorded in 2024.
- The largest annual shift saw Retained Earnings surged 19856.04% in 2022 before it plummeted 573.41% in 2025.
- AbCellera Biologics' Retained Earnings stood at $426.2 million in 2022, then crashed by 34.35% to $279.8 million in 2023, then crashed by 101.56% to -$4.4 million in 2024, then plummeted by 573.41% to -$29.5 million in 2025, then skyrocketed by 91.79% to -$2.4 million in 2026.
- Per Business Quant, the three most recent readings for ABCL's Retained Earnings are -$2.4 million (Q1 2026), -$29.5 million (Q4 2025), and -$20.5 million (Q3 2025).